2
Jun
2026

Enzymaster Deutschland GmbH

Exhibitor at CPHI Americas 2026 stand 1720
About Us

Combining AI-guided and computer aided enzyme discovery and enzyme engineering through the BioEngine® platform and the BioNavigator® toolbox, and large-scale manufacturing capabilities, Enzymaster enables companies to bring biocatalytic processes from concept to industrial production rapidly and efficiently. Enzymaster offers innovative chemical products based on biocatalytic routes, custom manufacturing of chemicals and enzymes from lab to tons-scale, rapid development enabled by extensive enzyme panels and AI-driven enzyme engineering, and ISO 9001-certified production of specialty chemicals

  • Country/Region:
    Germany
  • Founded:
    2013
  • On CPHI since:
    2021
  • Certificates:
    1
  • Employees:
    100 - 249
Company types
CMO/CDMO
Contract Research Organisation (CRO)
Manufacturer/Innovator
Primary activities
Contract Manufacturer
Contract Research Organisation
Custom Manufacturing/Custom Synthesis
Fine Chemicals Company
Intermediates Manufacturer
Contact info
Event information
CPHI Americas 2026
  • 2 Jun 2026 - 4 June 2026
  • Pennsylvania Convention Center, Philadelphia
  • Visit us at stand 1720

Products Featured at CPHI Americas 2026

Enzymaster Resources (1)

  • Brochure Enzymaster provides enzyme screening and engineering services

    Enzymaster is a one stop solution provider for the development and commercialization of innovative and sustainable enzyme catalysis technologies. With our proprietary BioEngine® platform and long-term experience, we offer R&D services with establishment of complete technology transfer packages and manufacturing collaborations to fine chemical, pharmaceutical and other industries.

    BioEngine® is our enzyme directed evolution platform, spearheaded by the integration of bioinformatics database guided design, computer protein modelling and simulations, as well as high throughput systems, thus highly efficient and reliable. The application of bioinformatics-assisted design and analysis of protein mutations leads to major time savings and higher success rates; whereas the automated and controlled laboratory procedures deliver higher accuracy and consistency of experimental results.